Rachel Loewy, PhD
Assistant adjunct professor, University of California, San Francisco
Dr. Loewy has disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.Demian Rose, PhD, MD
Assistant clinical professor, University of California, San Francisco
Dr. Rose hase disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
At the crossroads of these experiences lies the concept of the psychosis prodrome and early intervention/prevention efforts. But without evidence of a florid psychotic episode, when should one intervene?
P Ken Gillman, MBBS
Director, Psychotropical (www.psychotropical.com), Bucasia, Queensland, Australia
Dr. Gillman has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Any psychiatrist who has practiced during the last decade has probably written more than a few prescriptions for an atypical antipsychotic. But do these drugs provide any clear advantages over their predecessors?
Robert Rosenheck, MD
Professor of Psychiatry, Epidemiology and Public Health, and the Child Study Center, Yale Medical School
Dr Rosenheck has disclosed he received research support from Pfizer Pharmaceuticals to analyze CATIE data and has served as a consultant to Otsuka Pharmaceuticals on a long acting injectable antipsychotic. Dr. Balt has reviewed this article and found no evidence of bias in this educational activity.
Are the benefits of atypical antipsychotics based in reality? Dr. Rosenheck explains the stark difference between the SGAs of pharmaceutical myth and what has been proven with actual science.
Glen Spielmans, PhD
Associate professor of psychology, Metropolitan State University, St. Paul, MN
Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
Atypical antipsychotics are widely prescribed for a number of psychiatric diagnoses, but their real-world effectiveness has rarely been evaluated in anything other than short-term trials. A recently published study finds that four commonly used antipsychotics (aripiprazole [Abilify], olanzapine [Zyprexa], quetiapine [Seroquel], and risperidone [Risperdal]), when used in patients over age 40 with schizophrenia or psychosis associated with other conditions, may not be effective—and cause frequent side effects.
Today there are many scales to choose from. Psychiatrists familiar with these tools will be better able to interpret clinical trial results and to employ them in assessing patients’ clinical progress. Here we review the most commonly used depression rating scales, as well as some newer web-based tools.
You greet a new patient who complains of difficulty concentrating at work and is unable to “keep up” since making partner at a law firm or becoming an attending physician at a hospital. Is this an authentic case of a high-functioning person with undiagnosed adult ADHD, a subtle request for performance enhancement, or something altogether different?
Terence Keane, PhD
Professor and assistant dean for research, Boston University School of Medicine, Associate chief of staff for research & development, VA Boston Healthcare System
Dr. Keane has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
PTDS is one of the greatest mental health concerns in veterans, but there is a stigma, among veterans, on issues related to seeking mental health services. Dr. Kean discusses effective screening methods, current findings and treatment options.
Do you know what other medications your depressed patients are taking? You should. If they’re taking non-steroidal anti-inflammatory drugs (NSAIDs), they may be less likely to respond to SSRIs.